Atea Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview

Atea Pharmaceuticals

24/02/2025 22:19

* Atea Pharmaceuticals Inc  AVIR.OQ   AVIR.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 26 (estimated) for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Atea Pharmaceuticals Inc
is
for a loss of 37 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $6.20​, above​ its last closing price
of $3.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.46       -0.49      -0.37     Beat    25.3
 Jun. 30 2024  -0.76       -0.76      -0.48     Beat    37.3
 Mar. 31 2024  -0.63       -0.61      -0.75     Missed  -23.6​
 Dec. 31 2023  -0.49       -0.50      -0.47     Beat    5.4
 ​​Sep.        -0.45       -0.48      -0.40     Beat    16.1
 30 2023                                                
 Jun. 30 2023  -0.45       -0.47      -0.34     Beat    27.7​
 Mar. 31 2023  -0.47       -0.48      -0.43     Beat    9.9
 Dec. 31 2022  -0.44       -0.45      -0.41     Beat    8.9
 This summary was machine generated February 24 at 22:19 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)